Phosphorus ingestion improves oral glucose tolerance of healthy male subjects: a crossover experiment by unknown
RESEARCH Open Access
Phosphorus ingestion improves oral
glucose tolerance of healthy male subjects:
a crossover experiment
May Khattab1, Christelle Abi-Rashed1, Hala Ghattas1, Sani Hlais2 and Omar Obeid1*
Abstract
Background: Fasting serum phosphorus (P) was reported to be inversely related to serum glucose and insulin,
while the impact of P ingestion is not well documented. The effect of P intake with or before glucose ingestion on
postprandial glucose and insulin statuses was investigated.
Method: Two cross over experiments using healthy male subjects were conducted. Experiment 1: Overnight fasted
subjects (n = 7) randomly received: 500 mg of P tablets, glucose (75 g) solution with placebo or 500 mg of P
tablets. Experiment 2: Overnight fasted subjects (n = 8) underwent similar procedures to those of experiment 1,
except that placebo or 500 mg P tablets were given 60 min prior to glucose ingestion.
Results: In both experiments, serum P decreased following glucose ingestion. Co-ingestion of P with glucose
improved, at time 60 min, postprandial glucose (P < 0.05), insulin (P < 0.05), and insulin sensitivity index (p < 0.006),
while P pre-ingestion failed to exert similar effect.
Conclusion: This study suggests that postprandial glucose and insulin are affected by exogenous P supply,
especially when co-ingested with glucose.
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Introduction
Over the past few decades, the high prevalence of meta-
bolic syndrome has become a worldwide phenomenon,
associated with an increased risk and prevalence of type
2 diabetes mellitus [1]. This increasing phenomenon has
been found to be associated with dietary and lifestyle
changes, which favor the consumption of phosphorus
(P)-deficient food items [2]. In parallel, plasma phos-
phate levels were found to be synergistically related to
glucose tolerance and insulin sensitivity [3–5]. The asso-
ciation between P and glucose is believed to be mediated
by insulin [6], as a result of its capacity to stimulate both
P uptake by the muscles [7] and phosphorylation of
many compounds; thereby, creating a competition [8]
among these compounds for P.
Additionally, overweight and/or obesity, a known risk
factor for type 2 diabetes mellitus, is reported to be in-
versely related to plasma P [2, 3]. The intakes of high pro-
tein food choices, which are rich sources of P, have been
reported to improve weight loss [9] by a calcium inde-
pendent mechanism [10, 11]. Furthermore, the intake of
dairy products has been also found to be associated
with a lower risk for type 2 diabetes mellitus in three
meta-analyses of large prospective epidemiological studies
[12–15]. Moreover, since post-prandial glycaemia is a risk
factor for type 2 diabetes mellitus [16, 17], it is reasonable
to postulate that P is involved in its development. Several
dietary, lifestyle and pharmaceutical approaches have been
used to reduce postprandial glycaemia, including the en-
hancement of intracellular glucose trapping. Recently
glucokinase activators have been developed and tested,
but their capacity to improve glycaemia was associated
with several side effects [18–20] that may be attributed to
hepatic intracellular P depletion, especially since a limited
quantity of free P is present intracellularly.
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In brief, increased incidence of glucose intolerance
and type 2 diabetes mellitus is associated with dietary
changes that favor a reduction in the consumption of P,
an important mediator in glucose metabolism [5, 21–
23]. Despite the presence of evidence showing the ineffi-
ciency of fasting P to reflect its diurnal [24] or postpran-
dial status [25], a positive association between fasting P
levels and insulin sensitivity has been reported [26].
Micronutrients enrichment of carbohydrate meals was
reported to reduce post-prandial glycaemia [27]. Although
P is tightly integrated in the metabolism of glucose, the
impact of P ingestion on glucose tolerance and insulin
resistance of healthy subjects is not well documented.
However, phosphate infusion of healthy subjects was re-
ported to improve insulin sensitivity under euglycaemic
conditions [6] and phosphate supplementation of hypo-
phosphatemic glucose intolerant patients improved glucose
tolerance [28]. The aim of this study was to investigate
the effect of exogenous P on postprandial glucose and
insulin status in healthy subjects. Based on that, this study
holds significance in the advances of human nutrition in
improving glucose tolerance and therefore preventing the
development of type 2 diabetes mellitus in humans.
Subjects and methods
The study was comprised of two experiments. Healthy
male subjects were recruited to perform the experiments
(Table 1). Placebo (cellulose) or P (125 mg of potassium
phosphate per tablet) tablets, which had similar weight
and color, were administered to subjects in a random-
ized order to prevent order-of-treatment effect. The
study protocol was approved by the Institutional Review
Board committee at the American University of Beirut,
in addition to consent forms that have been obtained
from patients.
Experiment 1: the effect of phosphorus ingestion on oral
glucose tolerance test [OGTT]
Seven overnight fasted subjects (age (mean ± SEM): 23.2 ±
1.83 years; BMI: 22.65 ± 0.82 kg/m2) (Table 1: Experiment 1)
were asked to attend 3 experimental sessions that were
separated by a minimum of 3 days. Sessions included the
consumption of either 500 mg of P (4 tablets), a glucose
solution (75 g glucose) with 4 Placebo tablets, or a glucose
solution (75 g glucose) with 500 mg P. All were ingested
with 250 ml of cold water. Blood was withdrawn at base-
line and monitored till 240 min (min) after consumption.
Experiment 2: the effect of pre-phosphorus ingestion on
OGTT
Based on data from experiment 1, peak serum P concen-
tration (60 min) was associated with significant decrease
in serum glucose and insulin levels. Thus, experiment 2
was designed to investigate whether P intake one hour
prior to glucose ingestion would potentiate the effect of
P on postprandial glucose and insulin levels. Eight over-
night fasted subjects (age: 27.3 ± 1.68 years; BMI: 23.5 ±
0.97 kg/m2) (Table 1: Experiment 2) attended 2 experi-
mental sessions that were separated by a minimum of
3 days. Subjects were given placebo or P (500 mg) tab-
lets 60 min prior to glucose ingestion. Blood was drawn
at baseline (−60 min) and monitored till 240 min relative
to glucose ingestion.
Laboratory analyses
Serum was separated from collected blood samples and
stored at −80 °C for later analysis of glucose, total P, tri-
glyceride and insulin. Glucose was measured from ven-
ous samples. Insulin sensitivity was estimated by the
method of Caumo et al. [29] and expressed as (x
104 dl.kg−1.min−1.μUml−1). The method is based on the
kinetic of both glucose and insulin through coupling
their rate of appearance into circulation following oral
glucose ingestion. It is based on simple area under the
curve type of calculation and was validated in normal
subjects in whom their calculated insulin sensitivity was
strongly correlated to that of frequentl formula y sam-
pled iv glucose test (FSIGT) [29]. In addition, index of
insulin sensitivity was calculated using the composite
equation proposed by Matsuda and DeFronzo [30].
Statistical analyses
Data are presented as means ± SEM. Paired t-tests were
used to compare between treatments and to detect the
difference from baseline within each treatment. Repeated
Measure ANOVA was run to test the effect of treatment
Table 1 Characteristics of the study subjects
Characteristics Mean ± SEM
Experiment 1 (n = 7)
Age (years) 23.22 ± 1.83
Weight (kg) 68.88 ± 4.05
Height (m) 1.74 ± 0.02
BMI (kg/m2) 22.65 ± 0.82
Fasting glucose (mg/dl) 86.38 ± 1.62
Fasting triglycerides (mg/dl) 90.63 ± 15.9
Fasting phosphorus (mg/dl) 4.06 ± 0.19
Experiment 2 (n = 8)
Age (years) 27.3 ± 1.68
Weight (kg) 73 ± 4.78
Height (m) 1.76 ± 0.04
BMI (kg/m2) 23.5 ± 0.97
Fasting glucose (mg/dl) 88 ± 2.17
Fasting triglycerides (mg/dl) 119 ± 15.3
Fasting phosphorus (mg/dl) 3.75 ± 0.2
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groups over time on each of the dependent variables (P,
Glucose and insulin). The level of significance was fixed
at P < 0.05.
Results
Baseline serum levels of the different parameters (total P,
glucose, insulin) were similar between sessions and both
experiments (Table 1).
Experiment 1
Ingestion of P alone increased serum P significantly,
while ingestion of glucose alone decreased postprandial
serum P levels. The pattern of serum P changes follow-
ing glucose and P ingestion (G + P) was different than
that of the other two treatments (Fig. 1a), in line, re-
peated measures ANOVA showed that serum P was sig-
nificant according to treatment (Table 2: Experiment 1).
Fig. 1 Changes in Serum Phosphorus (a), Glucose (b) and Insulin (c) levels of subjects in experiment1. #Experiment 1: After the ingestion of
500 mg phosphorus (-♦-), 75 g glucose (-▲-) or co-ingestion glucose + phosphorus (75 g glucose + 500 mg of phosphorus) (..□..). * p-value < 0.05:
Paired t-test in the same treatment in comparison with baseline (time 0) value. a p-value < 0.05: Paired t-Test, phosphorus vs glucose treatments
at each time point. b p-value < 0.05: Paired t-Test, phosphorus vs glucose + phosphorus treatments at each time point. c p-value < 0.05: Paired t-Test,
glucose vs glucose + phosphorus treatments at each time point
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Postprandial serum glucose concentration of the P treat-
ment group significantly decreased by around 5 mg/dl
during the experimental session, but this minimal reduc-
tion is believed to be the result of fasting. Glucose inges-
tion increased postprandial serum glucose levels of both
treatments, glucose and G + P, but the magnitude of the
increase was significantly lower in the G + P as com-
pared to glucose treatment at time 60 min (P = 0.016),
(Fig. 1b). Repeated measures ANOVA showed that
serum glucose levels were significantly different accord-
ing to time, but failed to reach statistical significance be-
tween treatments (Table 2: Experiment 1).
Ingestion of P alone did not alter postprandial insulin
concentration. Insulin levels of the G + P treatment were
significantly lower (P = 0.002) than that of the glucose
treatment at time 60 min (Fig. 1c). Repeated measures
ANOVA found that serum insulin was significant ac-
cording to time only (Table 2: Experiment 1). Insulin
sensitivity obtained from oral glucose tolerance test and
according to Caumo et al. [29] formula increased follow-
ing G + P treatment and the difference was close to sig-
nificance (P = 0.051) (Table 3: Experiment 1). While
index of insulin sensitivity increased significantly (P =
0.006) following the addition of P to OGTT (Table 3:
Experiment 1). Insulin sensitivity of the P ingestion
treatment was not determined since postprandial glu-
cose and insulin levels were minimally affected.
Experiment 2
Ingestion of placebo tablets had no effect on serum P
levels prior to glucose ingestion, but glucose ingestion
decreased serum P levels (Fig. 2a). Following P ingestion,
serum P levels increased significantly at time 0 and
15 min and then returned to baseline levels (Fig. 2a). Re-
peated measures ANOVA analysis of all time points
showed that serum P was significant according to time
and treatment (Table 2: Experiment 2). Serum glucose
levels of the glucose and G + P treatments increased sig-
nificantly following glucose ingestion (Fig. 2b). The in-
crease in glucose levels was similar between the two
treatments, except for a slight difference at time baseline
and 240 min believed to be of no clinical significance
(Fig. 2b). In line, repeated measures ANOVA were sig-
nificant according to time only (Table 2: Experiment 2).
Glucose ingestion increased insulin levels of both
treatments, but the magnitude of this increase was mod-
estly lower in the P preload treated group (Fig. 2c) and
repeated measures ANOVA failed to detect difference
according to treatment (Table 2: Experiment 2). Mea-
sures of insulin sensitivity were found to be similar be-
tween the two treatments and this was expected since
the changes in insulin and glucose were similar between
the treatments (Table 2: Experiment 2).
Discussion
In agreement with other studies, ingestion of P alone
(experiment 1 and 2) increased postprandial serum P
[31], while ingestion of grape juice [31], glucose alone
[32–34], or other type of carbohydrate [35] reduced
postprandial serum P levels. Glucose may indirectly
affect P status through the stimulation of peripheral P
uptake by insulin [7, 36, 37], which in turn stimulates
the phosphorylation of several compounds including
carbohydrate [35], fat and protein. About 60 % of in-
fused P has been reported to be translocated from the
extracellular to the intracellular compartment [6], mainly
in skeletal muscles [21, 36]. This translocation is be-
lieved to be mediated via insulin action as glucose infu-
sion in pancreatectomic dogs failed to induce a
reduction in serum P except when insulin became avail-
able [21, 37, 38]. In line with this, the parallel increase in
postprandial glucose and insulin (peaks at 30–60 min)
was followed by a decrease in serum P (dip at 90 min).
Therefore, under conditions of P intake alone, intracellu-
lar P is likely to have been affected since insulin was not
altered.
In the current study, both co- and pre-ingestion of P
were able to halt the drop in serum P levels following
glucose ingestion. In the G + P treatment, increased P
Table 2 Repeated measure ANOVA outcome variables
(Phosphorus, glucose and Insulin) of the two experiments
Outcome variables Time Treatment Interaction
Experiment 1 (n = 7)a (P value) (P value) (P value)
Serum Phosphorus 0.616 0.000 0.321
Serum Glucose 0.000 0.145 0.207
Serum Insulin 0.000 0.168 0.619
Experiment 2 (n = 8)
Serum Phosphorus 0.001 0.002 0.498
Serum Glucose 0.000 0.815 0.961
Serum Insulin 0.000 0.233 0.724
a Only glucose with placebo and glucose with P groups were included in
the analysis
Table 3 Measures of insulin sensitivity from oral glucose
tolerance test
Outcome variables Placebo Phosphorus Paired t-test
(P value)
Experiment 1 (n = 7)
Insulin sensitivity index [30] 5.69 ± 0.86 7.00 ± 1.06 0.006
Insulin sensitivity [29] 12.19 ± 3.85 20.22 ± 6.65 0.051
Experiment 2 (n = 8)
Insulin sensitivity index [30] 9.17 ± 0.97 8.88 ± 0.78 0.633
Insulin sensitivity [29] 15.31 ± 2.58 18.39 ± 3.28 0.210
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uptake and availability might have contributed to the drop
in glucose and insulin levels at time 60 min, due to an in-
crease in intracellular glucose trapping (phosphorylation),
especially since insulin release depends on glucose circula-
tion. This process might have played a role in the observed
improvement in the measures of insulin sensitivity following
P ingestion with glucose (Experiment 1). Phosphorylation or
P trapping seems to have been substantially stimulated or
became dependent on extracellular P 30 min after glucose
ingestion; as indicated by the drop in postprandial serum
P levels. This may partially be behind the failure of P pre-
ingestion to impact postprandial plasma glucose, since the
majority of phosphorus is known to be absorbed within
60 min, as supported by the finding from experiment 1.
Fig. 2 Changes in Serum Phosphorus (a), Glucose (b), and Insulin (c) levels of subjects in experiment2. #Experiment 2: After the he ingestion of
75 g glucose 60 min after placebo (-♦-) or 500 mg phosphors (..□..) preload. * p-value < 0.05: Paired t-test in the same treatment in comparison
with baseline (time −60 min) value. a p-value < 0.05: Paired t-Test between placebo and phosphorus preload treatments at each time point
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When glucose was ingested alone, the low availability of
P may have hindered insulin phosphorylation capacity
through creating competition for P. Such competition may
have deleterious effects since it can affect glucose clearance
and trapping, glycolysis and gluconeogenesis [39], and
phospholipids and hepatic fat accumulation [40]. Therefore,
postprandial glycemia and insulinemia seem to be improved
by exogenous P availability and this may partially explain
the reported association between low serum P with insulin
resistance and elevated blood glucose levels [5, 23].
Ingestion of P before or with glucose was able to pre-
vent the drop in postprandial serum P levels. The sus-
tained high postprandial serum P in the G + P treatment
in comparison to that of the glucose ingestion alone im-
plies that intracellular P uptake may be controlled by a
limited capacity for phosphorylation and/ or glucose up-
take. In healthy subjects, peripheral glucose uptake, es-
pecially in skeletal muscles, is known to be triggered by
insulin dependent Glut 4 stimulation [41]. While, intracel-
lular glucose phosphorylation is controlled by the activities
of glucokinase (liver) and hexokinase (muscle), the latter
has a low Vmax (maximum velocity) capacity and is highly
inhibited by glucose-P production [42]. The reduction in
serum glucose of the G + P treatment argues against a de-
fect in Glut 4 (glucose uptake), therefore the sustenance in
plasma P may have been attributed to the low Vmax
capacity of muscle hexokinase. Accordingly, ingestion of
higher P doses would not be expected to further improve
glucose, insulin, or insulin sensitivity.
The fact that P is absorbed along the entire intestinal
tract [22, 43] could be responsible for the observed high
plasma P levels (above baseline value) in the G + P treat-
ment beyond the time (120 min) of availability of glu-
cose and insulin. Moreover, the difference in the
magnitude of changes in postprandial glucose and insu-
lin levels between the preload and the co-ingestion ex-
periments implies that factors beyond the availability of
circulating P, glucose and insulin may have been in-
volved in improving of insulin sensitivity. The weak sig-
nificant association seen between P preload on insulin
sensitivity could be explained by the small sample size
of the present study. On the other hand, glucose-
phosphorus interaction in the proximal part of the small
intestine may been involved in insulin sensitivity through
incretin hormones. These hormones, especially glucagon
like peptide-1 (GLP-1) and gastric inhibitory polypeptide
(GIP) are known to be secreted in response to meal in-
gestion, especially high protein meals (rich in P) [9, 42]
and were reported to affect insulin status and to play
an important role in regulating postprandial blood
glucose [9, 44, 45].
The observed improvement in the measures of insulin
sensitivity following meal-phosphorus co-ingestion may
have been partially involved in the reported synergic
relationship between the intake of whole grains and glu-
cose tolerance [46]. Especially since this relationship was
not explained by the function of dietary fiber [47] and
whole grains are rich in phosphors. Additionally, our ob-
servation may partially explain the observed parallel rise
in metabolic syndrome with global urbanization and
westernization of dietary habits, which favor low P in-
take [3]. In comparison to other studies in the literature,
which have used P injections to study its effect on gly-
caemia and insulinemia [6], the current study used a dif-
ferent method that mimicked daily dietary habits,
through the ingestion of 500 mg of P with a glucose load
(approximately 1.7 mg of P per Kcal). Therefore, these
findings highlight the role of P in improving the states of
hyperglycemia and hyperinsulinemia in healthy individ-
uals without the influence of serum calcium and FGF-23
which did not vary when P is used [25].
On the other hand, elevated fasting serum P levels were
reported to be associated with mortality among patients
with chronic kidney [48] and coronary [49] diseases. The
association was partially explained by the capacity of high
P conditions to induce vascular calcification and endothe-
lial injury using in vitro studies [50–53]. Moreover, in a
human (in vivo) study endothelial function impair-
ment was apparent under high (1200 mg P/meal) and
not normal (400 mg P/meal) P ingestion [54]. In fact,
the negligible impact of dietary P intake on serum P
levels implies that factors associated with increased
serum P, rather than P intake, were probably behind
the association between cardiovascular disease and serum
P [24]. Recently, a weak association between dietary P in-
take and all-cause mortality was reported [55] and this
was questioned since participants adopted different
dietary patterns and P intake was not the only variable.
Thus, the nature of the relation between P intake and car-
diovascular disease and mortality is far from clear and re-
quires further scrutiny [56].
In the present study, sample size was based on the pre-
viously reported data of AUC for glucose [57]. However,
the observed large variations between subjects seem to
have diluted the impact of the interventions. Further stud-
ies, using a larger sample size, would help in exploring the
mechanisms by which the observed effects are mediated
especially by examining the role of incretin hormones.
The limitation of this study lies in its small number of
subjects enrolled into the experimental design. More-
over, although the dietary habits of these subjects were
not assessed prior to the initiation of the study; however,
as stated previously, fasting serum P status is not a good
indicator of P intake. Postprandial status of the mea-
sured parameters is not likely to be affected by prior
meal intake since all subjects were overnight fasted.
Therefore, assessing dietary habits of subjects has no
added implications on the study results.
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Conclusion
Ingestion of P with glucose was found to reduce post-
prandial glucose and insulin levels mainly at time
60 min. This was associated with a significant reduction
in insulin sensitivity index. These changes are likely to
have been attributed to phosphorus capacity to enhance
insulin mediated peripheral phosphorylation, which is
highly dependent on extracellular phosphorus availability
or exogenous (dietary) phosphorus supply. Dietary
phosphorus intake can exert its beneficial impact and
prevent the deleterious effect of depleting intracellular
phosphorus.
Abbreviations
P: Phosphorus; G: Glucose; G + P: Ingestion of glucose and phosphorus;
AUC: Area under the curve.
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